At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed squamous cell carcinoma of the head and neck from oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or unknown primary
- ✓Any disease stage allowed
- ✓No evidence of active disease
- ✓Must have undergone curative surgical resection, radiotherapy, and/or chemotherapy at least 1 month, but no more than 4 years ago
- ✕Myocardial infarction within the past 12 months
- ✕Uncontrolled congestive heart failure or unstable/uncontrolled angina
- ✕Malabsorption syndrome
- ✕Other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of cervix, or stage I-II cancer in complete remission
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study Examining the Feasibility of Long Term and Low Dose Oral Capecitabine (Xeloda®) in Newly Diagnosed Head and Neck Squamous Cell Carcinoma (HNSCC) After Surgery, Radiation and/or Chemotherapy
In Brief
A Phase 2 clinical trial evaluating capecitabine and Surgery, chemotherapy and/or radiotherapy for Head and Neck Cancer. Completed, enrolled 35 participants across 1 site.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving capecitabine after surgery, radiation therapy, and/or chemotherapy may kill any remaining tumor cells. PURPOSE: This phase II trial is studying how well capecitabine works in treating patients who have undergone previous surgery, radiation therapy, and/or chemotherapy for head and neck cancer.
Study Details
Timeline
Interventions
Capecitabine 1000mg/day for one year
Surgery, chemotherapy and/or radiotherapy